Early drug intervention reduces risk of cardiovascular events in rheumatoid arthritis sufferers – U of T Study

July 8, 2019

Share Post

People who develop rheumatoid arthritis (RA) as older adults, benefit from early and sustained use of a drug called Methotrexate (MTX), a treatment considered by many rheumatologists to be a first line of defense in managingHand Of Woman Deformed From Rheumatoid Arthritis the disease. Now, a new study led by Jessica Widdifield, an assistant professor at the Institute of Health Policy Management and Evaluation, has found that patients who have access to MTX earlier in their diagnosis, also reduce their risk of cardiovascular events associated with the disease.

“Rheumatoid arthritis is an inflammatory disease, and patients who develop the condition at an older age have a higher disease activity and inflammation in their joints,” says Widdifield who is also a scientist at Sunnybrook Research Institute and ICES. “This type of chronic systemic inflammation has been linked to atherogenesis, a disease of the arteries, but MTX may also influence this type of inflammation throughout the body, reducing a patient’s cardiovascular risk.”

While MTX as a drug has been vetted for safety and efficacy, it is also a chemotherapeutic agent and an immunosuppressive drug, which means that some family physicians just aren’t comfortable prescribing it. Early access to treatment for rheumatoid arthritis is dependent on a patient’s ability to see a rheumatologist, creating a barrier for older adults that can delay the effectiveness of the drug.

“There are many factors that delay access to treatment, one of which is a shortage of rheumatologists, which leads to longer wait times,” says Widdifield. “Another is that patients might delay presenting to primary care physicians thinking that they are suffering with just arthritis or symptoms of getting older.”

Profile of Jessica Widdifield with green foliage in background
Jessica Widdifield

Widdifield also notes that primary care physicians may not always recognize signs and symptoms of rheumatoid arthritis and the urgency of a referral to a rheumatologist. Further delays in treatment may also result from a rheumatologist opting to use another form of treatment other than MTX.

Each of these barriers can have a negative impact on the ability of MTX to diminish long-term risks including cardiovascular events and even delay helping patients end up remission. According to the study, within the first year of diagnosis, patients who were treated with MTX experienced a lower rate of cardiovascular events, and those that were given the drug continuously and assessed in the last 12 months, reduced their risk by 20%.

Widdifield’s study is the first of its kind to examine the evidence around the effect of timing of MTX initiation in relation to long-term outcomes. With evidence already in place showing that early MTX treatment helped patients end up in remission from the disease, Widdifield felt it was imperative to also assess whether early treatment also reduced cardiovascular risks.

“Our evidence supports the recommendation that rheumatoid arthritis patients should receive methotrexate treatment early and continue to receive it in order to control the disease and reduce their risk of a cardiovascular event,” says Widdifield.

Her study also demonstrates the importance of rheumatologists in providing timely care. In Canada, Widdifield points out that the supply of rheumatologists has not kept up with the needs of our growing and aging population, increasing the burden of symptoms and risks on patients with rheumatoid arthritis.

“We have made great strides in improving care and outcomes for Canadians with rheumatoid arthritis,” says Widdifield, “but future patients may not have the same experience if we don’t also address the impending shortage and maldistribution of rheumatologists across the country.”

Related News

Image of a doctor meeting with a patient

Public Trust Crucial for Use of Administrative Health Data in Identifying Future Health Risks  

March 6, 2024

Faculty / Research

Read More
Image of Kerry Kuluski Emily Cordeaux and Yasmin Sheikhan

New Funding Program Inspired by IHPME Students and Faculty Supports Student Research and Patient Partnerships 

January 24, 2024

Faculty / Research / Students

Read More
Image of the world with a grid of faces behind it

New Academic Centre Unites Four Health Sciences Faculties to Address Global Ecological Change

December 7, 2023

Research

Read More
Valeria Rac

Dr. Valeria Rac named Canada Research Chair in Health System and Technology Evaluation

December 6, 2023

Faculty / Research

Read More

OHT Impact Fellows help build a learning health system in Ontario

August 14, 2023

Research

Read More

IHPME student wins third grant for work in digital health research

June 12, 2023

Awards / Research / Students

Read More

Sign up for IHPME Connect.

Keep up to date with IHPME’s News & Research, Events & Program, Recognition, e-newsletter.

* indicates required

Get in Contact


Communications

TBD
Email Address: ihpme.communications@​utoronto.ca

Manages all IHPME-wide communications and marketing initiatives, including events and announcements.